IL1B and head and neck squamous cell carcinoma: IL-1β treatment enhanced resistance of FaDu and OECM-1 cells to DTX (Supplemental Figure 7, A and B), whereas anakinra sensitized CM-treated HNSCC cells to DTX (Figure 5I).